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ABSTRACT
Background: Obesity in Prader-Willi syndrome (PWS) seems to
be related to a low basal metabolic rate (BMR). In addition,
abnormal sleep patterns reported in PWS might affect sleeping
metabolic rate (SMR).
Objective: Our objective was to assess BMR and SMR adjusted
for fat-free mass in young PWS patients.
Design: Subjects were 17 PWS patients (10 females and 7 males
aged 7.5–19.8 y) and 17 obese control subjects matched for sex
and bone age. SMR was measured in a respiratory chamber,
BMR with a ventilated-hood system, and body composition by
deuterium dilution.
Results: BMR and SMR were significantly lower in the PWS
group than in the control group (5.36 – 1.18 and 4.62 – 1.08 MJ/d
compared with 6.38 – 1.55 and 5.60 – 1.52 MJ/d, respectively;
P < 0.05). When fat-free mass was included in the analysis, mul-
tiple regression showed no differences in BMR and SMR between
groups. When weight was included in the analysis instead of fat-
free mass, SMR was lower in the PWS group. Fat-free mass was
lower in the PWS group both as an absolute value and when
adjusted for height.
Conclusion: BMR and SMR are low in young patients with
PWS because of a low fat-free mass. Am J Clin Nutr 2000;
71:752–6.
KEY WORDS Prader-Willi syndrome, obesity, child, energy
metabolism, body composition, bone age, fat-free mass, basal
metabolic rate, sleeping metabolic rate
INTRODUCTION
Prader-Willi syndrome (PWS; 1) is a clinically diagnosed
genetic disorder that results from the absence of normally active
paternally inherited genes at chromosome 15(q11–q13) (2).
About 70–75% of the patients have an interstitial deletion in this
region. The majority of the remaining PWS patients have a
maternal uniparental disomy for chromosome 15. The major
clinical criteria (3) for the diagnosis of PWS include neonatal
and infantile central hypotonia with feeding problems in infancy,
hypogonadism, and global developmental delay resulting in
mild-to-moderate mental retardation (4). Other symptoms, such
as short stature, altered temperature sensitivity, high pain thresh-
old, and characteristic behavior problems (eg, temper tantrums
or obsessive-compulsive behavior), support the hypothesis that
dysfunction of various hypothalamic systems are the probable
pathophysiologic basis of PWS (5–7). PWS is also known as the
most common human genetic disorder linked to obesity (8). The
high prevalence of obesity in PWS is likely caused by a combi-
nation of a low energy expenditure and an almost insatiable
hunger that starts in early childhood (9, 10).
Schoeller et al (11) were the first to report that common for-
mulas that use age, sex, height, and weight to predict basal meta-
bolic rate (BMR) would overestimate BMR in adult PWS
patients. They found that the Cunningham formula (12), which
uses fat-free mass (FFM) in the equation, did not significantly
overestimate BMR. Later studies, however, either could not con-
firm the reduced BMR in young PWS patients (13) or found a
reduced BMR, even when BMR was adjusted for FFM (14). The
question, therefore, of whether BMR adjusted for FFM is
reduced in young PWS patients is still unanswered.
BMR is composed of 2 components, sleeping metabolic rate
(SMR) and arousal. The respiratory chamber measures SMR
overnight and offers an alternative measurement of metabolic
rate in the inactive and fasted state. In addition, parents and
caregivers often report excessive sleepiness, daytime hypersom-
nolence, and sleep disturbance at night in PWS patients. Studies
have shown abnormal sleep and sleep cycles with abnormal
rapid eye movement (REM) and multiple brief REM periods,
suggesting a specific disruption of the timing of REM–non-
REM cycles (15–17), possibly causing an alteration in SMR in
patients with PWS.
As a result of contradictory reports of BMR and of abnor-
mal sleep patterns in patients with PWS, the aim of our study
was to measure BMR and SMR adjusted for FFM in children
and adolescents with PWS in comparison with those of obese
control subjects.
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SUBJECTS AND METHODS
Subjects
Seventeen PWS patients (aged 7.5–19.8 y) were recruited
with the assistance of the Dutch Prader-Willi Association. The
subjects were assessed according to the Holm criteria (3). The
Holm system provides a quantitative measure of PWS symp-
toms. PWS was preferably confirmed by either a deletion on
chromosome 15 or uniparental disomy. When only clinical data
were available, a critical evaluation was done by the same clinical
geneticist. The PWS subjects were sex- and bone age–matched
with healthy obese control subjects (aged 6.3–15.3 y) recruited
from the regional public health department. Bone age was deter-
mined by assessing epiphysial maturation by the same pediatric
endocrinologist using an X-ray of the midportion of the left hand
and standard growth data (18). None of the PWS patients was
receiving hormone therapy or treatment with human growth hor-
mone before or during the study. Control subjects with endocrine
causes or other secondary causes of obesity were excluded. Sub-
ject characteristics are shown in Table 1.
Before the start of the study the parents gave written, informed
consent confirmed by oral approval of the child. The study was
approved by the Medical Ethical Committee of Maastricht
University.
Methods
SMR was measured overnight in a respiratory chamber. After
this, BMR and body composition were determined by ventilated
hood and deuterium dilution, respectively. The subject and
parent were invited to come to the laboratory at 1900 after a
normal dinner. At 2200, the subject entered the respiratory
chamber. The hours in between were used to familiarize the sub-
ject with the study equipment, do a practice session with the
ventilated hood, and produce a background urine sample for
body-composition analysis.
Body composition was measured with a dilution technique
according to the Maastricht protocol (19). In summary, the sub-
ject received an orally administered dose of 0.1 g D2O/L total
body water (TBW), diluted in 75 mL tap water, as the last drink
before bedtime. TBW was estimated from age- and sex-specific
formulas (20). After dosing, the subject went into the respiratory
chamber and was asked to go to sleep before 2230. A urine sam-
ple was taken from the second voiding the next morning, 10 h
after dose administration. Isotope abundance in urine was deter-
mined with an isotope ratio mass spectrometer.
TBW was calculated as the 2H dilution space divided by 1.04 to
correct for exchange of the 2H label with nonaqueous hydrogen of
body solids (21). FFM was assessed with the assumption that FFM
contained all body water. Hydration factors of FFM were based on
maturation-specific values (22). Maturation was assessed accord-
ing to Tanner’s puberty ratings (23). Fat mass (FM) was calculated
by subtracting FFM from the subject’s total body weight. To allow
for comparisons between subjects, FM and FFM were expressed
as indexes: FFMI (kg/m2) and FMI (kg/m2), respectively. Patients
with PWS experience specific periods of growth stunting, leading
to changes in age-related body composition. In this way, we cor-
rected for the large variation in height, in analogy with body mass
index (BMI; in kg/m2): BMI = FFMI + FMI.
SMR was measured during a 12-h overnight stay in the respi-
ratory chamber, which was described in detail previously (24).
The respiratory chamber, an open-circuit indirect calorimeter
(14 m3), was maintained at a constant air temperature of 18 8C
during the night. The chamber was ventilated with fresh air at
<40 L/min. Activity of the subject was measured by using an
analogue ultrasound radar system. SMR was calculated automat-
ically according to de Weir (25), between 2300 and 0630, over the
3-h interval with the lowest radar count. The next morning, the
subject came out of the respiratory chamber at 0630 to void and
immediately returned to bed for BMR measurement in an adja-
cent room. Because the subject was not active that morning, the
BMR measurement was started after they laid supine for 10 min.
Oxygen consumption and carbon dioxide production were
measured by a computerized, open-circuit, ventilated-hood sys-
tem between 0700 and 0800 for 40–50 min, while the subject
was lying supine watching television. Gas analyses were per-
formed by using a paramagnetic oxygen analyzer (Servomex,
Crowborough, United Kingdom) and an infrared carbon dioxide
analyzer (Servomex). BMR was calculated according to de
Weir’s formula over the 14-min interval with the lowest SD.
The body weight of subjects was measured on an electronic
scale (model E1200; Mettler, Greifensee, Switzerland) before
the subjects consumed any food or drink, after voiding, and
while wearing underclothing. The height of subjects was meas-
ured by using a stadiometer.
Statistical analysis
Differences between the independent variables of the PWS
group and those of the control group were analyzed by using the
two-sample t test. The grouping variable PWS was defined as
PWS patients = 1, control subjects = 0. A multiple linear regres-
sion model with BMR as the dependent variable and bone age,
FFM, FM, sex, and PWS status as independent variables was used
to analyze the differences between groups adjusted for these inde-
pendent variables. First, the difference in regression slope of the
influence of FFM on BMR was tested by using an interaction
variable of PWS and FFM (PWS 3 FFM) after correction for the
variables in the equation. Second, the difference between groups,
again corrected for these independent variables, was estimated
and tested for significance by using linear regression, assuming
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TABLE 1
Body composition, energy expenditure, and other characteristics of
subjects with Prader-Willi syndrome (PWS) and control subjects1
PWS Control
(n = 10 F, 7 M) (n = 10 F, 7 M)
Bone age (y) 12.7 – 2.9 12.7 – 3.2
Age (y) 11.9 – 3.4 11.3 – 2.6
Height (m) 1.43 – 0.16 1.49 – 0.20
Weight (kg) 50.0 – 19.7 61.5 – 25.6
FFM (kg) 27.5 – 9.92 35.9 – 13.4
FM (kg) 22.4 – 11.7 25.6 – 12.7
BMI (kg/m2) 23.5 – 6.0 26.0 – 6.5
FFMI (kg/m2) 12.9 – 2.33 15.4 – 2.7
FMI (kg/m2) 10.6 – 4.5 10.6 – 4.0
SMR (MJd) 4.62 – 1.082 5.60 – 1.52
BMR (MJ/d) 5.36 – 1.182 6.38 – 1.55
1 x– – SD. FFM, fat-free mass; FM, fat mass; FFMI, fat-free mass
index; FMI, fat mass index; SMR, sleeping metabolic rate; BMR, basal
metabolic rate.
2,3 Significantly different from control group (independent-samples
t test): 2 P < 0.05, 3 P < 0.01.
equal slopes. This analysis was also done for SMR as the depen-
dent variable, but now with weight, bone age, sex, and PWS sta-
tus as the independent variables by using an interaction variable
of PWS status and weight (PWS 3 weight). The significance
level was chosen at 5%. Data were expressed as means – SDs.
SPSS, release 6.1, for Macintosh (SPSS Inc, Chicago) was used.
RESULTS
Clinical characteristics of PWS patients and control subjects
are shown in Table 1. There were no significant differences in
age, height, weight, or BMI between groups. FFM and FFMI
were significantly lower in the PWS group, and FM and FMI
were similar in both groups. SMR and BMR were also signifi-
cantly lower in the PWS group than in the control group. FFM
was plotted against BMR in Figure 1. When BMR was expressed
as a function of FFM in separate linear regression lines for the
PWS and control groups, the R2 values were 0.91 and 0.83,
respectively. These lines were not significantly different, as was
evident from multiple regression when BMR was predicted by
bone age, FFM, FM, and sex with PWS status as the grouping
variable. The coefficients of bone age and FM were also not
significant (Table 2). When SMR was plotted as a function of
FFM, the regression lines of the PWS group and the control group
were remarkably similar (Figure 2). In Table 3 the observed vari-
ability in SMR was explained by the variables bone age, sex,
weight, and PWS status, resulting in a significant difference in
SMR between groups. FFMI was plotted as a function of FMI
(Figure 3). In this plot, the difference between the regression
lines was significant. Because the interaction variables PWS 3
FFM and PWS 3 weight were not significant in the regression
analyses, these variables were not included in the related tables.
DISCUSSION
The present study showed that children and adolescents with
PWS had a lower energy expenditure both during rest and during
sleep than did sex- and bone age–matched control subjects. Pre-
vious reports indicating a lower than average BMR in this syn-
drome were based on studies of small groups of adult PWS
patients and were without control groups (21, 26). In a more
recent study that measured BMR in children and adolescents
(13), 10 subjects with PWS were compared with a cohort of
60 healthy schoolchildren. Although the difference in BMR
between groups was not significant, the difference decreased fur-
ther after adjustment for age, sex, and FFM. Therefore, to study
the relation between FFM and energy expenditure in PWS, a
control group is needed that is matched for age and sex.
However, most children with PWS have a delay in biological
maturation, possibly because of the suggested hypothalamic
insufficiencies. Calendar age often overestimates the physical
development of a PWS child (8). Bone age measurement, as a
means of assessing the rate of maturational change throughout
the growing period, provides an estimate of physiologic matura-
tion (27). Thus, in the present study, the control group was
matched for sex and bone age.
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TABLE 2
Results of multiple linear regression analysis of the influence of bone age,
fat-free mass, fat mass, sex, and Prader-Willi syndrome (PWS) on basal
metabolic rate (BMR)
Variable b Coefficient1 SE 95% CI b2 P
Bone age (y) 0.017 0.055 (20.095, 0.129) 0.756
FFM (kg) 0.096 0.017 ( 0.061, 0.131) 0.000
Fat mass (kg) 0.014 0.013 (20.012, 0.039) 0.285
Sex 20.548 0.179 (20.916, 20.181) 0.005
PWS3 20.175 0.204 (20.593, 0.244) 0.399
1 Partial regression coefficient: the change in BMR for a change in a spe-
cific variable adjusted for the other independent variables in the equation.
2 Range of values that includes the population value of the coefficient.
3 Grouping variable PWS was defined as follows: PWS patients = 1, con-
trol subjects = 0; the interaction variable PWS 3 FFM was not significant.
FIGURE 1. Basal metabolic rate (BMR) as a function of fat-free mass
(FFM) plotted for the Prader-Willi syndrome (PWS; d) and control (u)
groups. The regression equation for PWS patients: BMR = 0.11 FFM +
2.21 (R2 = 0.91); for control subjects: BMR = 0.11 FFM + 2.60 (R2 = 0.83).
FIGURE 2. Sleeping metabolic rate (SMR) as a function of fat-free
mass (FFM) for the Prader-Willi syndrome (PWS; d) and control (u)
groups. The regression equation for PWS patients: SMR = 0.11 FFM +
1.70 (R2 = 0.94); for control subjects: SMR = 0.11 FFM + 1.73 (R2 = 0.91).
To adjust BMR for FFM, BMR was plotted as a function of
FFM. Because FFM explained > 87% of the observed variability
in BMR, the reduction in BMR must mainly be the result of a
low FFM. Indeed, the similarity of the regression lines of the
groups indicates that the relation between FFM and BMR in
PWS was comparable with the relation in healthy children. In
addition, there was a small, nonsignificant difference in inter-
cepts between the 2 groups, but equal slopes for the lines. This
finding differs from that of Hill et al (14), who found a lower
BMR in PWS patients, even when adjusted for FFM, than in
2 groups of lean and obese control subjects. The authors sug-
gested that persons with PWS have low energy expenditures
early in life, but which become normal as these patients grow
older and obesity becomes greater. In the present study, neither
bone age nor FM significantly explained the observed variability
in BMR with FFM in a multiple regression analysis. Moreover,
PWS status was not important in predicting BMR when adjusted
for FFM. A possible explanation for this conflicting result might
be that this study used bioelectrical impedance analysis to meas-
ure FFM instead of a dilution technique. The high correlation
between the skinfold-thickness measurements and the results of
bioelectrical impedance analysis especially suggests that the lat-
ter may overestimate actual FFM because skinfold thicknesses
are known to underestimate the amount of FM in PWS on
account of the altered distribution of body fat (11). Another rea-
son might be that the differences within and between studies are
caused by the residual variability of the BMR measurement. Pre-
vious studies have reported that it was difficult for children with
PWS to lay quietly for a BMR measurement, often resulting in
no satisfactory measurement at all (13, 14). The measurement of
SMR overnight in the respiratory chamber reduced the influence
of agitation on the measurement. Thus, FFM explained 93% of
the observed variability. Other variables such as FM, sex, and
bone age, therefore, only played a minor role in the prediction of
SMR. However, when body weight instead of FFM is used to
predict SMR, the grouping variable PWS is significant, even
when adjusted for bone age and sex, indicating that young PWS
patients have a low SMR.
Thus, a low BMR and SMR must be the result of a low FFM. In
the present study, FFM was significantly lower in the PWS group,
both as an absolute value and when adjusted for height (FFMI).
FFMI is an objective measure for comparing healthy subjects with
patients with growth deficiency. Indeed, when corrected for height,
the difference in FFM in the present study was even more signifi-
cant (P < 0.01). Furthermore, it is also necessary to adjust FFM for
the effect of FM because an increase in FM will induce an increase
in FFM. When FFMI was plotted as a function of FMI, however,
the slope of the PWS group was significantly lower than that of the
control group, indicating that for each unit increase in FM the
increase in FFM will be relatively lower in PWS patients.
The precise etiology of the reduction in growth of FFM in
PWS is still unclear. The profound hypotonia in PWS might pre-
vent the child from becoming physically active, resulting in low
stimulation of muscle and bone tissue, consequently leading to a
growth deficit of FFM.
A more general explanation relates the deficit in FFM to a
dysfunction of the hypothalamic systems. Abnormalities of the
somatotrophic axis would explain why most patients have a
blunted growth hormone response to various provocative stimuli
or show low 24-h growth hormone secretion (28–31). In addi-
tion, reduced concentrations of gonadotropins, consistent with
hypogonadotropic hypogonadism, suggest a dysfunction of the
hypothalamic-pituitary-gonadal axis (6). Although a structural
hypothalamic lesion has not been found, a recent study found a
complete absence of the posterior pituitary bright spot on mag-
netic resonance imaging, indicating disturbed functioning of the
hypothalamic-hypophyseal system (7). The administration of
growth hormone to subjects with PWS in several studies had a
positive effect on height and reduced percentage body fat (29,
32, 33). Currently, prolonged trials of growth hormone treatment
are underway to explore different dosage regimens and possible
long-term adverse effects of these interventions.
In conclusion, this is the first report that shows energy expen-
diture to be lower at rest as well as during sleep in children and
adolescents with PWS than in obese control subjects matched for
bone age and sex. The reduced energy expenditure is the result
of low FFM, both as an absolute value and when adjusted for
height. There was no significant difference in energy expenditure
between normal children and those with PWS when BMR or
SMR was adjusted for FFM.
ENERGY EXPENDITURE IN PRADER-WILLI SYNDROME 755
TABLE 3
Results of multiple linear regression analysis of the influence of bone age,
sex, weight, and Prader-Willi syndrome (PWS) on sleeping metabolic rate
(SMR)
Variable b Coefficient1 SE 95% CI b2 P
Bone age 0.039 0.043 (20.050, 0.128) 0.380
Sex 20.505 0.149 (20.810, 0.200) 0.002
Weight 0.052 0.006 (0.040, 0.064) 0.000
PWS3 20.380 0.157 (20.701, 0.059) 0.022
1 Partial regression coefficient: the change in SMR for a change in a spe-
cific variable adjusted for the other independent variables in the equation.
2 Range of values that includes the population value of the coefficient.
3 Grouping variable PWS was defined as follows: PWS patients = 1, con-
trol subjects = 0; the interaction variable PWS 3 weight was not significant.
FIGURE 3. Fat-free mass index (FFMI) as a function of fat mass
index (FMI) plotted for the Prader-Willi syndrome (PWS; d) and con-
trol (u) groups. The regression line of the PWS patients is significantly
different from the regression line of the control subjects, P < 0.001 (mul-
tiple linear regression analysis).
756 VAN MIL ET AL
REFERENCES
1. Prader A, Labhart A, Willi H. Ein Syndrom von Adipositas, Klein-
wuchs, Kryptorchismus und Oligophrenie nach myatonieartigem
Zustand in Neugeborenenalter. (A syndrome of adiposity, short
stature, hypogonadism and hypomentia after hypotonia in the new-
born.) Schweiz Med Wochenschr 1956;86:1260–1 (in German).
2. Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M. Genetic
imprinting suggested by maternal heterodisomy in nondeletion
Prader-Willi syndrome. Nature 1989;342:281–5.
3. Holm VA, Cassidy SZ, Butler MG, et al. Prader-Willi syndrome:
consensus diagnostic criteria. Pediatrics 1993;91:398–402.
4. Curfs LMG, Fryns J-P. Prader-Willi syndrome: a review with spe-
cial attention to the cognitive and behavioral profile. In: Evers-
Kiebooms G, Fryns J-P, Cassiman JJ, Berghe HV, ed. Psychosocial
aspects of genetic counseling. New York: Wiley-Liss, 1992:
99–104.
5. Swaab DF. Development of the human hypothalamus. Neurochem
Res 1995;20:509–19.
6. Swaab DF. Prader-Willi syndrome and the hypothalamus. Acta Paed-
iatr Suppl 1997;423:50–4.
7. Miller L, Angulo M, Price D, Taneja S. MR of the pituitary in
patients with Prader-Willi syndrome: size determination and imag-
ing findings. Pediatr Radiol 1996;26:43–7.
8. Cassidy SB. Prader-Willi syndrome and other chromosome 15q dele-
tion disorders. Noordwijkerhout, Netherlands: Springer-Verlag, 1991.
9. Coplin SS, Hine J, Gormican A. Out-patient dietary management in
the Prader-Willi syndrome. J Am Diet Assoc 1976;68:330–4.
10. Holm VA, Pipes PL. Food and children with Prader-Willi syndrome.
Am J Dis Child 1976;130:1063–7.
11. Schoeller DA, Levitsky LL, Bandini LG, Dietz WW, Walczak A.
Energy expenditure and body composition in Prader-Willi syn-
drome. Metabolism 1988;37:115–20.
12. Cunningham JJ. An individualization of dietary requirements for
energy in adults. J Am Diet Assoc 1982;80:335–8.
13. Davies PSW, Joughin C. Using stable isotopes to assess reduced
physical activity of individuals with Prader-Willi syndrome. Am J
Ment Retard 1993;98:349–53.
14. Hill JO, Kaler M, Spetalnick B, Reed G, Butler MC. Resting meta-
bolic rate in Prader-Willi syndrome. Dysmorphol Clin Genet 1990;
4:27–32.
15. Bueno AV, Kales A, Soldatos CR. Sleep in the Prader-Willi syndrome:
clinical and polygraphic findings. Arch Neurol 1984;41:294–6.
16. Hertz G, Cataletto M, Feinsilver SH, Angulo M. Sleep and breath-
ing patterns in patients with Prader-Willi syndrome (PWS): effects
of age and gender. Sleep 1993;16:366–71.
17. Clift S, Dahlitz M, Parker JD. Sleep apnoea in the Prader-Willi syn-
drome. J Sleep Res 1994;3:121–6.
18. Tanner JM, Whitehouse RH, Marshall WA, Healy MJR, Goldstein
H. Assessment of skeletal maturity and prediction of adult height
(TW2 Method). London: Academic Press, 1983.
19. Westerterp KR, Wouters L, van Marken-Lichtenbelt WD. The Maas-
tricht protocol for the measurement of body composition and energy
expenditure with labeled water. Obes Res 1995;3:49–57.
20. Cheek DB, Mellits D, Elliott D. Body water, height, and weight dur-
ing growth in normal children. Am J Dis Child 1966;112:312–7.
21. Schoeller DA, van Santen E, Petterson DW, Dietz W, Jaspan J, Klein
PD. Total body water measurement in humans with 18O and 2H
labeled water. Am J Clin Nutr 1980;33:2686–93.
22. Boileau RA, Lohman TG, Slaughter MH, Ball TE, Going SB, Hen-
drix MK. Hydration of the fat-free body in children during matura-
tion. Hum Biol 1984;56:651–66.
23. Tanner JM. Growth at adolescence. London: Blackwell Scientific
Publications Ltd, 1962:1–301.
24. Schoffelen PFM, Westerterp KR, Saris WHM, Hoor FT. A dual-res-
piration chamber system with automated calibration. J Appl Physiol
1997;83:2064–72.
25. de Weir JB. New methods for calculating metabolic rate with spe-
cial reference to protein metabolism. J Physiol 1949;612:511–21.
26. Bakke BL, Draheim CC, Mendoza W, Serfass RC. Metabolic rate dur-
ing rest and exercise in adults with Prader-Willi syndrome. Tenth annual
scientific conference of the Prader-Willi Syndrome Association (USA),
Seattle, Washington. Am J Med Genet 1995;64:577 (abstr no. 9).
27. Cox LA. The biology of bone maturation and ageing. Acta Paediatr
Suppl 1997;423:107–8.
28. Costeff H, Holm VA, Ruvalcaba R, Shaver J. Growth hormone
secretion in Prader-Willi syndrome. Acta Paediatr Scand 1990;
79:1059–62.
29. Lee PD, Hwu K, Henson H, et al. Body composition studies in Prader-
Willi syndrome: effects of growth hormone therapy. In: Ellis KJ, East-
man JD, eds. Human body composition. Houston: Plenum Press,
1993:201–7.
30. Angelo M, Castro-Magna M, Uv J, Rosenberg W. Growth hormone
evaluation and treatment in Prader-Willi syndrome. Pediatr Res 1991;
29:126A (abstr).
31. Cappa M, Grossi A, Borrelli P, et al. Growth hormone (GH)
response to combined pyridostigmine and GH-releasing hormone
administration in patients with Prader-Labhart-Willi syndrome.
Horm Res 1993;39:51–5.
32. Lee PDK, Wilson DM, Rountree L, Hintz RL, Rosenfeld RG. Lin-
ear growth response to exogenous growth hormone in Prader-Willi
syndrome. Am J Med Genet 1987;28:865–71.
33. Lindgren AC, Hagenas L, Muller J, et al. Growth hormone treatment
of children with Prader-Willi syndrome affects linear growth and
body composition favourably. Acta Paediatr 1998;87:28–31.
